



# AETERNA ZENTARIS INC.

## FORM 6-K

(Report Of Foreign Issuer)

Filed 03/27/24 for the Period Ending 03/27/24

Address C/O NORTON ROSE FULBRIGHT CANADA LLP, TORONTO,  
A6, M5K 1E7

Telephone (727) 384-2323

CIK 0001113423

Symbol AEZS

SIC Code 2834 - Pharmaceutical Preparations

Fiscal Year 12/31

Powered by **barchart**

<https://www.barchart.com/solutions>

© Copyright 2022, Barchart.com, Inc. All Rights Reserved.

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2024

Commission File Number: **001-38064**

**Aeterna Zentaris Inc.**  
(Translation of registrant's name into English)

**c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---



On March 26, 2024, the registrant filed in Canada its consolidated financial statements and Management's Discussion and Analysis as of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021, with the Canadian Securities Administration.

**DOCUMENTS INDEX**

<b>Exhibit</b>	<b>Description</b>
99.1	<a href="#">The Registrant's Annual Audited Consolidated Financial Statements as at December 31, 2023 and December 31, 2022 and for the years ended December 31, 2023, 2022 and 2021</a>
99.2	<a href="#">The Registrant's Management's Discussion and Analysis of Financial Condition and Results of Operations for the financial year ended December 31, 2023</a>

(2)

---



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**AETERNA ZENTARIS INC.**

Date: March 26, 2024

By: /s/ Klaus Paulini

Klaus Paulini  
President and Chief Executive Officer

(3)

---